|
"su w c"的相关文件
显示项目 6-30 / 419 (共17页)
1 2 3 4 5 6 7 8 9 10 > >>
每页显示[10|25|50]项目
| 國立成功大學 |
2023 |
Polygenic Risk Score, Environmental Tobacco Smoke, and Risk of Lung Adenocarcinoma in Never-Smoking Women in Taiwan
|
Blechter, Blechter B.;Chien, L.-H.;Chen, T.-Y.;Chang, I.-S.;Choudhury, P.P.;Hsiao, C.-F.;Shu, X.-O.;Wong, J.Y.Y.;Chen, K.-Y.;Chang, G.-C.;Tsai, Y.-H.;Su, W.-C.;Huang, M.-S.;Chen, Y.-M.;Chen, Chen C.-Y.;Hung, Hung H.-H.;Hu, J.-W.;Shi, J.;Zheng, W.;Rositch, A.F.;Chen, Chen C.-J.;Chatterjee, N.;Yang, P.-C.;Rothman, N.;Hsiung, C.A.;Lan, Q. |
| 國立成功大學 |
2023 |
Occupational evaluation of community-based psychiatric rehabilitation outcomes in individuals with severe mental illnesses: A ten-year retrospective study
|
Liu, Y.-C.;Yang, Yang Y.K.;Lee, Y.-C.;Lin, S.-H.;Hsu, W.-Y.;Su, W.-C.;Chen, K.C.;Lin, K.-C. |
| 國立成功大學 |
2023 |
A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-na�ve, cisplatin-ineligible urothelial cancer
|
Galffy, Galffy G.;Lugowska, I.;Poddubskaya, E.V.;Cho, B.C.;Ahn, M.-J.;Han, J.-Y.;Su, W.-C.;Hauke, R.J.;Dyar, S.H.;Lee, D.H.;Serwatowski, P.;Estelles, D.L.;Holden, V.R.;Kim, Y.J.;Vladimirov, Vladimirov V.;Horvath, Z.;Ghose, A.;Goldman, A.;di, Pietro A.;Wang, J.;Murphy, D.A.;Alhadab, Alhadab A.;Laskov, M. |
| 國立成功大學 |
2023 |
Thiamet G as a Potential Treatment for Polycystic Kidney Disease
|
Su, W.-C.;Hung, C.-F.;Wang, Y.-C.;Peng, H.;Huang, W.-H.;Lo, Y.-L.;Lo, Y.-H.;Chen, Y.-C.;Su, H.-H.;Chen, Y.-L. |
| 國立成功大學 |
2023 |
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
|
Sequist, L.V.;Yang, J.C.-H.;Yamamoto, N.;O'Byrne, K.;Hirsh, V.;Mok, T.;Geater, S.L.;Orlov, S.;Tsai, C.-M.;Boyer, M.;Su, W.-C.;Bennouna, J.;Kato, T.;Gorbunova, V.;Lee, K.H.;Shah, R.;Massey, D.;Zazulina, V.;Shahidi, M.;Schuler, M. |
| 國立成功大學 |
2023 |
Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study
|
Chiu, Chiu C.-H.;Lin, M.-C.;Wei, Y.-F.;Chang, G.-C.;Su, W.-C.;Hsia, T.-C.;Su, J.;Wang, A.K.-F.;Jen, M.-H.;Puri, T.;Shih, J.-Y. |
| 國立成功大學 |
2023 |
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer
|
Camidge, D.R.;Barlesi, F.;Goldman, J.W.;Morgensztern, D.;Heist, R.;Vokes, E.;Spira, A.;Angevin, E.;Su, W.-C.;Hong, D.S.;Strickler, J.H.;Motwani, Motwani M.;Dunbar, M.;Parikh, A.;Noon, E.;Blot, V.;Wu, J.;Kelly, Kelly K. |
| 國立成功大學 |
2023 |
PTPN23 ubiquitination by WDR4 suppresses EGFR and c-MET degradation to define a lung cancer therapeutic target
|
Singh, Singh S.;Yeat, N.Y.;Wang, Y.-T.;Lin, S.-Y.;Kuo, I.-Y.;Wu, K.-P.;Wang, Wang W.-J.;Wang, Wang W.-C.;Su, W.-C.;Wang, Y.-C.;Chen, R.-H. |
| 國立成功大學 |
2023 |
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
|
Tsuboi, M.;Herbst, R.S.;John, T.;Kato, T.;Majem, Majem M.;Groh�, C.;Wang, J.;Goldman, J.W.;Lu, S.;Su, W.-C.;De, Marinis F.;Shepherd, F.A.;Lee, K.H.;Le, N.T.;Dechaphunkul, A.;Kowalski, D.;Poole, L.;Bolanos, A.;Rukazenkov, Y.;Wu, Y.-L. |
| 國立成功大學 |
2023 |
Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study
|
Yang, J.C.-H.;Su, W.-C.;Chiu, Chiu C.-H.;Shiah, H.-S.;Lee, K.-Y.;Hsia, T.-C.;Uno, M.;Crawford, N.;Terakawa, H.;Chen, W.-C.;Takayama, G.;Hsu, C.;Hong, Y.;Saintilien, C.;McGill, J.;Chang, G.-C. |
| 臺大學術典藏 |
2022-09-15T01:09:00Z |
Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts
|
Bang Y.-J.; Su W.-C.; Schuler M.; Nam D.-H.; Lim W.T.; Bauer T.M.; Azaro A.; Poon R.T.P.; Hong D.; Chia-Chi Lin; Akimov M.; Ghebremariam S.; Zhao S.; Giovannini M.; Ma B. |
| 臺大學術典藏 |
2022-09-15T01:08:50Z |
Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: The PACT phase Ia/Ib trial
|
Patnaik A.; Yap T.A.; Chung H.C.; de Miguel M.J.; Bang Y.-J.; Chia-Chi Lin; Su W.-C.; Italiano A.; Chow K.H.; Szpurka A.M.; Yu D.; Zhao Y.; Carlsen M.; Schmidt S.; Vangerow B.; Gandhi L.; Xu X.; Bendell J. |
| 臺大學術典藏 |
2022-09-15T01:08:49Z |
Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors
|
Shiah H.-S.; Chiang N.-J.; Chia-Chi Lin; Yen C.-J.; Tsai H.-J.; Wu S.-Y.; Su W.-C.; Chang K.-Y.; Wang C.-C.; Chang J.-Y.; Chen L.-T. |
| 臺大學術典藏 |
2022-09-15T01:08:46Z |
Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
|
Park K.; Tan D.S.W.; Su W.-C.; Cho B.C.; Kim S.-W.; Lee K.H.; Wang C.-C.; Seto T.; Huang D.C.-L.; Jung H.H.; Hsu M.-C.; Bogenrieder T.; Chia-Chi Lin |
| 臺大學術典藏 |
2022-09-15T01:08:45Z |
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: Results from a phase I/II open-label, multicenter study
|
Zucali P.A.; Chia-Chi Lin; Carthon B.C.; Bauer T.M.; Tucci M.; Italiano A.; Iacovelli R.; Su W.-C.; Massard C.; Saleh M.; Daniele G.; Greystoke A.; Gutierrez M.; Pant S.; Shen Y.-C.; Perrino M.; Meng R.; Abbadessa G.; Lee H.; Dong Y.; Chiron M.; Wang R.; Loumagne L.; L?pine L.; De Bono J. |
| 臺大學術典藏 |
2022-09-15T01:08:45Z |
Safety and Antitumor Activity of a-PD-L1 Antibody as Monotherapy or in Combination witha-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors
|
Hollebecque A.; Chung H.C.; Miguel M.J.D.; Italiano A.; MacHiels J.-P.; Chia-Chi Lin; Dhani N.C.; Peeters M.; Moreno V.; Su W.-C.; Chow K.H.; Galvao V.R.; Carlse M.; Yu D.; Szpurka A.M.; Zhao Y.; Schmidt S.L.; Gandhi L.; Xu X.; Bang Y.-J. |
| 臺大學術典藏 |
2022-08-10T02:37:42Z |
Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study
|
CHIH-HSIN YANG; Reckamp K.L.; Kim Y.-C.; Novello S.; Smit E.F.; Lee J.-S.; Su W.-C.; Akerley W.L.; Blakely C.M.; Groen H.J.M.; Bazhenova L.; Carcereny Costa E.; Chiari R.; Hsia T.-C.; Golsorkhi T.; Despain D.; Shih D.; Popat S.; Wakelee H. |
| 臺大學術典藏 |
2022-08-10T02:37:42Z |
Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan
|
Chen Y.-M.; CHIH-HSIN YANG; Su W.-C.; Chong I.-W.; Hsia T.-C.; Lin M.-C.; Chang G.-C.; Chiu C.-H.; Ho C.-C.; Wu S.-Y.; Hung J.-Y.; Wang C.-C.; Yang T.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2022-08-10T02:37:37Z |
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial
|
Lu S.; Wang Q.; Zhang G.; Dong X.; Yang C.-T.; Song Y.; Chang G.-C.; Lu Y.; Pan H.; Chiu C.-H.; Wang Z.; Feng J.; Zhou J.; Xu X.; Guo R.; Chen J.; Yang H.; Chen Y.; Yu Z.; Shiah H.-S.; Wang C.-C.; Yang N.; Fang J.; Wang P.; Wang K.; Hu Y.; He J.; Shi J.; Chen S.; Wu Q.; Sun C.; Li C.; Wei H.; Cheng Y.; Su W.-C.; Hsia T.-C.; Cui J.; Sun Y.; Ou S.-H.I.; Zhu V.W.; CHIH-HSIN YANG |
| 臺大學術典藏 |
2022-08-10T02:37:37Z |
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer
|
J?nne P.A.; Baik C.; Su W.-C.; Johnson M.L.; Hayashi H.; Nishio M.; Kim D.-W.; Koczywas M.; Gold K.A.; Steuer C.E.; Murakami H.; CHIH-HSIN YANG; Kim S.-W.; Vigliotti M.; Shi R.; Qi Z.; Qiu Y.; Zhao L.; Sternberg D.; Yu C.; Yu H.A. |
| 臺大學術典藏 |
2022-06-27T07:07:55Z |
High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy
|
Perng R.-P.; Yang C.-H.; Chen Y.-M.; Chang G.-C.; Lin M.-C.; Hsieh R.-K.; Chu N.-M.; Lai R.-S.; Su W.-C.; Tsao C.-J.; Hsia T.-C.; Chen H.-C.; Chen C.-H.; Huang M.-S.; Wang J.-L.; Ho M.-L.; Chung C.-Y.; CHONG-JEN YU; Chang W.-C.; Kuo H.-P.; Yu C.-T.; Lin Z.-Z.; Kao W.-Y. |
| 臺大學術典藏 |
2022-06-27T07:07:41Z |
The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia
|
Hsiung C.A.; Lan Q.; Hong Y.C.; Chen C.-J.; Dean Hosgood H.; Chang I.-S.; Chatterjee N.; Brennan P.; Wu C.; Zheng W.; Chang G.-C.; Wu T.; Park J.Y.; Hsiao C.-F.; Kim Y.H.; Shen H.; Seow A.; Yeager M.; Tsai Y.-H.; Kim Y.T.; Chow W.-H.; Guo H.; Wang W.-C.; Sung S.W.; Hu Z.; Chen K.-Y.; Kim J.H.; Chen Y.; Huang L.; Lee K.-M.; Lo Y.-L.; Gao Y.-T.; Kim J.H.; Liu L.; Huang M.-S.; Jung T.H.; Jin G.; Caporaso N.; Yu D.; Kim C.H.; Su W.-C.; Shu X.-O.; Xu P.; Kim I.-S.; Chen Y.-M.; Ma H.; Shen M.; Cha S.I.; Tan W.; Chang C.-H.; Sung J.S.; Zhang M.; Yang T.-Y.; Park K.H.; Yuenger J.; Wang C.-L.; Ryu J.-S.; Xiang Y.; Deng Q.; Hutchinson A.; Kim J.S.; Cai Q.; Landi M.T.; CHONG-JEN YU; Park J.-Y.; Tucker M.; Hung J.-Y.; Lin C.-C.; Perng R.-P.; Boffetta P.; Chen C.-Y.; Chen K.-C.; Yang S.-Y.; Hu C.-Y.; Chang C.-K.; Fraumeni Jr. J.F.; Chanock S.; Yang P.-C.; Rothman N.; Lin D. |
| 臺大學術典藏 |
2022-06-27T07:02:08Z |
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial
|
Yang J.C.H.; Shih J.-Y.; Su W.-C.; Hsia T.-C.; Tsai C.-M.; Ou S.H.I.; CHONG-JEN YU; Chang G.-C.; Ho C.-L.; Sequist L.V.; Dudek A.Z.; Shahidi M.; Cong X.J.; Lorence R.M.; Yang P.-C.; Miller V.A. |
| 臺大學術典藏 |
2022-06-27T07:02:06Z |
Genetic variant in TP63 on locus 3q28 is associated with risk of lung adenocarcinoma among never-smoking females in Asia
|
Hosgood III H.D.; Wang W.-C.; Hong Y.-C.; Wang J.-C.; Chen K.; Chang I.-S.; Chen C.-J.; Lu D.; Yin Z.; Wu C.; Zheng W.; Qian B.; Park J.Y.; Kim Y.H.; Chatterjee N.; Chen Y.; Chang G.-C.; Hsiao C.-F.; Yeager M.; Tsai Y.-H.; Wei H.; Kim Y.T.; Wu W.; Zhao Z.; Chow W.-H.; Zhu X.; Lo Y.-L.; Sung S.W.; Chen K.-Y.; Yuenger J.; Kim J.H.; Huang L.; Chen Y.-H.; Gao Y.-T.; Kim J.H.; Huang M.-S.; Jung T.H.; Caporaso N.; Zhao X.; Huan Z.; Yu D.; Kim C.H.; Su W.-C.; Shu X.-O.; Kim I.-S.; Bassig B.; Chen Y.-M.; Cha S.I.; Tan W.; Chen H.; Yang T.-Y.; Sung J.S.; Wang C.-L.; Li X.; Park K.H.; CHONG-JEN YU; Ryu J.-S.; Xiang Y.; Hutchinson A.; Kim J.S.; Cai Q.; Landi M.T.; Lee K.-M.; Hung J.-Y.; Park J.-Y.; Tucker M.; Lin C.-C.; Ren Y.; Perng R.-P.; Chen C.-Y.; Jin L.; Chen K.-C.; Li Y.-J.; Chiu Y.-F.; Tsai F.-Y.; Yang P.-C.; Fraumeni Jr. J.F.; Seow A.; Lin D.; Zhou B.; Chanock S.; Hsiung C.A.; Rothman N.; Lan Q. |
| 臺大學術典藏 |
2022-06-27T07:02:03Z |
Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia
|
Lan Q.; Hsiung C.A.; Matsuo K.; Hong Y.-C.; Seow A.; Wang Z.; Hosgood H.D.; Chen K.; Wang J.-C.; Chatterjee N.; Hu W.; Wong M.P.; Zheng W.; Caporaso N.; Park J.Y.; Chen C.-J.; Kim Y.H.; Kim Y.T.; Landi M.T.; Shen H.; Lawrence C.; Burdett L.; Yeager M.; Yuenger J.; Jacobs K.B.; Chang I.-S.; Mitsudomi T.; Kim H.N.; Chang G.-C.; Bassig B.A.; Tucker M.; Wei F.; Yin Z.; Wu C.; An S.-J.; Qian B.; Lee V.H.F.; Lu D.; Liu J.; Jeon H.-S.; Hsiao C.-F.; Sung J.S.; Kim J.H.; Gao Y.-T.; Tsai Y.-H.; Jung Y.J.; Guo H.; Hu Z.; Hutchinson A.; Wang W.-C.; Klein R.; Chung C.C.; Oh I.-J.; Chen K.-Y.; Berndt S.I.; He X.; Wu W.; Chang J.; Zhang X.-C.; Huang M.-S.; Zheng H.; Wang J.; Zhao X.; Li Y.; Choi J.E.; Su W.-C.; Park K.H.; Sung S.W.; Shu X.-O.; Chen Y.-M.; Liu L.; Kang C.H.; Hu L.; Chen C.-H.; Pao W.; Kim Y.-C.; Yang T.-Y.; Xu J.; Guan P.; Tan W.; Su J.; Wang C.-L.; Li H.; Sihoe A.D.L.; Zhao Z.; Chen Y.; Choi Y.Y.; Hung J.-Y.; Kim J.S.; Yoon H.-I.; Cai Q.; Lin C.-C.; Park I.K.; Xu P.; Dong J.; Kim C.; He Q.; Perng R.-P.; Kohno T.; Kweon S.-S.; Chen C.-Y.; Vermeulen R.; Wu J.; Lim W.-Y.; Chen K.-C.; Chow W.-H.; Ji B.-T.; Chan J.K.C.; Chu M.; Li Y.-J.; Yokota J.; Li J.; Chen H.; Xiang Y.-B.; CHONG-JEN YU; Kunitoh H.; Wu G.; Jin L.; Lo Y.-L.; Shiraishi K.; Chen Y.-H.; Lin H.-C.; Wu T.; Wu Y.-L.; Yang P.-C.; Zhou B.; Shin M.-H.; Fraumeni J.F.; Lin D.; Chanock S.J.; Rothman N. |
显示项目 6-30 / 419 (共17页)
1 2 3 4 5 6 7 8 9 10 > >>
每页显示[10|25|50]项目
|
